Mitchell L Shiffman

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
    Richard K Sterling
    Section of Hepatology, Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298 0341, USA
    Am J Gastroenterol 99:866-72. 2004
  2. ncbi Chronic hepatitis C in patients with persistently normal alanine transaminase levels
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA, and Hospital General de Valencia, Spain
    Clin Gastroenterol Hepatol 4:645-52. 2006
  3. ncbi Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Hepatology 46:371-9. 2007
  4. ncbi Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    N Engl J Med 357:124-34. 2007
  5. ncbi What future for ribavirin?
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Int 29:68-73. 2009
  6. ncbi Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Clin Liver Dis 12:487-505, vii. 2008
  7. ncbi Role and support for hepatologists at liver transplant programs in the United States
    Mitchell L Shiffman
    Hepatology Section and Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Transpl 14:1092-9. 2008
  8. ncbi Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
  9. ncbi Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Gastroenterology 137:1986-94. 2009
  10. ncbi Retreatment of chronic hepatitis C virus infection in patients who failed to achieve sustained virologic response
    M L Shiffman
    Hepatology Section, Virginia Commonwealth, University Medical Center, Richmond, VA 23298, USA
    Minerva Gastroenterol Dietol 50:37-49. 2004

Collaborators

Detail Information

Publications101 found, 100 shown here

  1. ncbi Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
    Richard K Sterling
    Section of Hepatology, Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298 0341, USA
    Am J Gastroenterol 99:866-72. 2004
    ..The present study describes our experience of treating HCV in the inmate population of the Virginia Department of Corrections...
  2. ncbi Chronic hepatitis C in patients with persistently normal alanine transaminase levels
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA, and Hospital General de Valencia, Spain
    Clin Gastroenterol Hepatol 4:645-52. 2006
    ..We compared characteristics of chronic hepatitis C patients with patients with normal and elevated ALT levels using data from 3 randomized phase III trials of peginterferon alfa-2a (40 kDa)...
  3. ncbi Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Hepatology 46:371-9. 2007
    ..In contrast, a higher starting dose of RVN was associated with a lower relapse rate and higher rate of SVR...
  4. ncbi Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    N Engl J Med 357:124-34. 2007
    ..We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin...
  5. ncbi What future for ribavirin?
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Int 29:68-73. 2009
    ..However, based on the results of clinical trials conducted to date, it is much more likely that peginterferon, not ribavirin, could be expendable...
  6. ncbi Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Clin Liver Dis 12:487-505, vii. 2008
    ..This review discusses strategies to optimize peginterferon and ribavirin dosing and the impact that growth factors may have on the ability to achieve a sustained virologic response...
  7. ncbi Role and support for hepatologists at liver transplant programs in the United States
    Mitchell L Shiffman
    Hepatology Section and Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Transpl 14:1092-9. 2008
    ..The current shortage of transplant hepatologists is likely to increase if appropriate support mechanisms are not implemented...
  8. ncbi Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
    ..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
  9. ncbi Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Gastroenterology 137:1986-94. 2009
    ..This analysis was performed to determine whether suppressing HCV RNA during the trial was associated with a reduction in clinical outcomes...
  10. ncbi Retreatment of chronic hepatitis C virus infection in patients who failed to achieve sustained virologic response
    M L Shiffman
    Hepatology Section, Virginia Commonwealth, University Medical Center, Richmond, VA 23298, USA
    Minerva Gastroenterol Dietol 50:37-49. 2004
    ..This manuscript will review the factors to consider when assessing such patients, the likelihood of achieving an SVR with current therapy and options for patients who continue to manifest non-response...
  11. ncbi Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation
    R Todd Stravitz
    Section of Hepatology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Liver Transpl 10:850-8. 2004
    ..In conclusion, interferon treatment of recurrent hepatitis C does not consistently improve histologic disease after virologic response, and it may increase the risk of allograft rejection...
  12. ncbi Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  13. ncbi A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation
    Nevin Yilmaz
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Transpl 13:975-83. 2007
    ..However, complications associated with sepsis, not recurrent cirrhosis, was the most common cause of death in patients with recurrent HCV and this was similar in patients with or without advanced fibrosis...
  14. ncbi A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans
    Richard K Sterling
    Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond 23298 0341, USA
    Clin Gastroenterol Hepatol 2:469-73. 2004
    ..Differences in hepatitis C virus (HCV)-related liver disease between Caucasians and African Americans remain controversial...
  15. ncbi The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV
    Richard K Sterling
    Hepatology Section and Division of Pathology, Virginia Commonwealth University Health System, Richmond, Virginia
    Am J Gastroenterol 100:313-21. 2005
    ....
  16. ncbi Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation
    R Todd Stravitz
    Section of Hepatology, Division of Gastroenterology, Hume Lee Transplant Center, Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Liver Int 32:1138-45. 2012
    ..However, the use of HBIg has many disadvantages...
  17. ncbi Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection
    Richard K Sterling
    Virginia Commonwealth University, Medical College of Virginia, Richmond, USA
    Clin Gastroenterol Hepatol 2:432-9. 2004
    ....
  18. ncbi Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C
    Arun J Sanyal
    Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, VA 23298 0341, USA
    Hepatology 43:682-9. 2006
    ..It is also associated with a lower rate of development of ascites, hyperbilirubinemia, and hepatocellular carcinoma. However, cardiovascular mortality is greater in patients with NASH...
  19. ncbi Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298, USA
    Curr Gastroenterol Rep 8:46-52. 2006
    ....
  20. ncbi Controversies in the management of hepatitis C virus infection after liver transplantation
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Liver Transpl 9:1129-44. 2003
    ....
  21. ncbi Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples
    Richard K Sterling
    Virginia Commonwealth University Health System, Richmond, USA
    Clin Gastroenterol Hepatol 8:1070-6. 2010
    ..However, no studies have directly compared fibrosis progression by paired liver biopsy between patients infected with HIV and HCV versus those infected with only HCV...
  22. ncbi Management of patients with chronic hepatitis C virus infection and previous nonresponse
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    Rev Gastroenterol Disord 4:S22-30. 2004
    ..This article reviews the factors to consider when assessing nonresponders for additional therapy and options for patients with continued nonresponse...
  23. ncbi Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin
    Moises Diago
    Hepatology Section, Hospital General de Valencia, Valencia, Spain
    Hepatology 51:1897-903. 2010
    ..Abbreviated regimens may be considered in patients with a low baseline viral load who achieve an RVR...
  24. ncbi Effect of hyponatraemia on outcomes following orthotopic liver transplantation
    William A Hackworth
    Liver Transplant Program, Hume Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    Liver Int 29:1071-7. 2009
    ..Aims: To assess impact of pretransplant hyponatraemia on post-transplant outcomes...
  25. ncbi Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes
    Jenny O Smith
    Hepatology Section and Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    Liver Transpl 15:273-9. 2009
    ..Efforts to modify those factors that contribute to PLOS may reduce this event, improve survival, and reduce OLT-associated costs...
  26. ncbi Retreatment of patients who do not respond to initial therapy for chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298, USA
    Cleve Clin J Med 71:S13-6. 2004
    ..Long-term maintenance therapy with pegylated interferon is currently being evaluated in nonresponders with advanced fibrosis and cirrhosis. Its use should be considered investigational at this time...
  27. ncbi Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years
    Nevin Yilmaz
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Liver Int 28:72-8. 2008
    ..Maintaining a serum anti-HB surface level above a minimum arbitrary titre of 200 pg/mL did not appear to be necessary for effective HBIG prophylaxis...
  28. ncbi Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome
    Arun J Sanyal
    Department of Pathology, Virginia Commonwealth University Health System, Richmond, Virginia, USA
    Am J Gastroenterol 98:2064-71. 2003
    ..Advanced fibrosis in such patients is related to weight, presence of diabetes, and presence and degree of cytological ballooning...
  29. ncbi Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA
    Am J Gastroenterol 102:761-6. 2007
    ..These results suggest that African Americans have a global defect in their ability to eradicate HCV infection following treatment with interferon and ribavirin which transcends across all genotypes...
  30. ncbi Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation
    Mitchell L Shiffman
    Hepatology Section, Division of Surgical Pathology, Virginia Commonwealth University Medical Center, Richmond, VA, 23298, USA
    Liver Transpl 10:1248-55. 2004
    ..9, compared with 59% with fibrosis and a mean score of.9 after LDLT. In conclusion, these data strongly suggest that fibrosis progression from recurrent HCV is not more severe in patients after LDLT...
  31. ncbi A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis
    Jonathan T Hlivko
    Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0341, USA
    Clin Gastroenterol Hepatol 6:1036-40. 2008
    ..Although this regimen achieves remission in approximately 80%, some patients are intolerant or do not respond. Mycophenolate mofetil (MMF) is a potent immunosuppressant. However, its utility in AIH is not well-defined...
  32. ncbi Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival
    Daniel G Maluf
    Department of Surgery, Hume Lee Transplant Center, Virginia Commonwealth University, Richmond, VA 23298 0248, USA
    Transplantation 83:853-7. 2007
    ..This study aimed to evaluate the outcomes of our HCV+/end-stage renal disease (ESRD) patient population based on the therapeutic option including KTx or continuation in dialysis...
  33. ncbi Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA, USA mshiffma vcu edu
    Oncology 78:11-6. 2010
    ..Based upon the available data, there appears to be no rationale for utilizing Peg-IFN maintenance therapy in patients with cirrhosis and this approach does not reduce the risk of HCC...
  34. ncbi The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome
    Onpan Cheung
    Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Richmond, VA 23298, USA
    Hepatology 46:1091-100. 2007
    ..However, DCL is most strongly associated with severity of steatohepatitis. WC and BMI added modestly to the contribution of DCL to severity of nonalcoholic steatohepatitis...
  35. ncbi Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection
    Richard K Sterling
    Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0341, USA
    Hepatology 47:1118-27. 2008
    ..Although we did identify genotype 3, increased BMI, and diabetes as risk factors, we found no independent association with antiretroviral therapy...
  36. ncbi Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome
    Richard Todd Stravitz
    Section of Hepatology, Hume Lee Transplant Center of Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Am J Med 121:119-26. 2008
    ..We hypothesized that the quality of surveillance for hepatocellular carcinoma influences prognosis by affecting access to liver transplantation...
  37. ncbi Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation
    Robert A Fisher
    Department of Surgery, Division of Transplantation, Virginia Commonwealth University Health Systems at Medical College of Virginia Hospitals, Richmond, 23298 0254, USA
    Clin Transplant 18:463-72. 2004
    ..The goal of this study was to evaluate a multidrug approach that would reduce both early and long-term morbidity related to immunosuppression while maintaining an acceptable freedom from rejection...
  38. ncbi The clinical spectrum of hepatitis C virus in HIV coinfection
    Richard K Sterling
    Section of Hepatology, Virginia Commonwealth University Health System Medical College of Virginia Hospitals, Richmond, Virginia, USA
    J Acquir Immune Defic Syndr 32:30-7. 2003
    ..The spectrum of liver disease in coinfection includes a significant proportion of patients with normal ALT values, and excluding these patients from previous studies has led to an overestimation of HCV disease severity...
  39. ncbi Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C
    Onpan Cheung
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    J Clin Gastroenterol 45:76-82. 2011
    ..However, the impact of mild-moderate alcohol use on the severity of liver fibrosis is unclear...
  40. ncbi Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System Medical College of Virginia, Richmond, Virginia 23298, USA
    Am J Gastroenterol 98:1159-66. 2003
    ..The present study was performed to evaluate the impact of the international unit standard for measuring HCV RNA in the management of patients with chronic hepatitis C virus (HCV) infection...
  41. ncbi A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Comonwealth University Medical Center, Richmond, VA 23298 0711, USA
    Clin Gastroenterol Hepatol 2:1107-15. 2004
    ....
  42. ncbi Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response
    Amrita Sethi
    Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298, USA
    Clin Liver Dis 9:453-71, vii-viii. 2005
    ..The management of these patients creates a formidable challenge. This article outlines various strategies for patients who have failed to achieve SVR and discusses the merits of different approaches to management...
  43. ncbi Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis
    Erik Seth Kramer
    Department of Epidemiology and Community Health, Virginia Commonwealth University, Richmond, VA 23298 0341, USA
    Dig Dis Sci 54:2016-25. 2009
    ....
  44. ncbi Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values
    Pouneh Mofrad
    Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
    Hepatology 37:1286-92. 2003
    ....
  45. ncbi Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C
    R Todd Stravitz
    Section of Hepatology, Division of Gastroenterology and the Division of Hematology/Oncology, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298-0341, USA
    Am J Gastroenterol 100:1415-9. 2005
    ..PRCA caused by the development of erythropoietin antibodies is a potentially life-threatening complication of administering epoetin alfa to prevent the anemia associated with antiviral therapy in patients with chronic hepatitis C...
  46. ncbi Hepatitis C with normal liver enzymes: to treat or not to treat. A balancing view: a decision to be shared with patients
    Mitchell L Shiffman
    Hepatology Section, Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Am J Gastroenterol 99:975-6. 2004
  47. ncbi Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals, Richmond, VA 23298, USA
    Liver Transpl 9:S14-20. 2003
    ..4. Achieving a sustained virological response after treatment with interferon, with or without ribavirin, is associated with a reduced risk for the development of cirrhosis and HCC and prolonged survival...
  48. ncbi Side effects of medical therapy for chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, 23298, USA
    Ann Hepatol 3:5-10. 2004
    ..Appropriate recognition and management of these side effects will both improve response to therapy and avoid unnecessary morbidity and mortality...
  49. ncbi Use of diagnostic testing for managing hepatitis C virus infection
    Andrea Ferreira-Gonzalez
    Division of Molecular Diagnostics, Department of Pathology, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA
    Semin Liver Dis 24:9-18. 2004
    ..In contrast, changes in serum HCV RNA level are important predictors of virological response to treatment with pegylated interferon and ribavirin...
  50. ncbi Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus
    M Fernanda Sábato
    Molecular Diagnostics Laboratory, Department of Pathology, Virginia Commonwealth University, Richmond, Virginia 23298 0248, USA
    J Clin Microbiol 45:2529-36. 2007
    ..19 log(10) IU/ml. Our study demonstrates that Roche RUO-MPLC and Abbott ASR-Q provided acceptable results and agreed sufficiently with the COBAS Amplicor HCV Monitor v2.0...
  51. ncbi Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment
    Mitchell L Shiffman
    Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    J Clin Pharmacol 51:1293-301. 2011
    ..Therefore, the results do not support daily ADV dosing using a liquid suspension over the current strategy of adjustment of the ADV dosing interval in patients with impaired renal function...
  52. ncbi Management of acute hepatitis B
    Mitchell L Shiffman
    Bon Secours Health System, Liver Institute of Virginia, Richmond, VA, USA
    Clin Liver Dis 14:75-91; viii-ix. 2010
    ..However, the use of an oral anti-HBV agent is not unreasonable to use in a patient who is developing acute liver failure from severe acute HBV...
  53. ncbi Retreatment of patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Medical College of Virginia, Richmond, VA 23298, USA
    Hepatology 36:S128-34. 2002
    ..These results help to focus retreatment with peginterferon and ribavirin on subsets of patients who are most likely to benefit...
  54. ncbi Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent
    Adrian H Cotterell
    Division of Transplantation Surgery, Department of Surgery, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, VA, USA
    Clin Transplant 16:49-51. 2002
    ..Rapamycin is an effective replacement agent as primary immunosuppressive therapy following withdrawal of CNIs in liver transplant patients with CNI-induced chronic nephrotoxicity...
  55. ncbi Living donor liver transplantation: summary of a conference at The National Institutes of Health
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Richmond, VA, USA
    Liver Transpl 8:174-88. 2002
    ....
  56. ncbi Management of interferon therapy nonresponders
    M L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Richmond, Virginia, USA
    Clin Liver Dis 5:1025-43. 2001
    ..The efficacy of peginterferon and peginterferon with ribavirin for nonresponders has yet to be defined...
  57. ncbi A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis
    R K Sterling
    Division of Gastroenterology and Hepatology, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Aliment Pharmacol Ther 20:943-9. 2004
    ..Mycophenolate mofetil is a potent immunosuppressant that is now widely used in organ transplantation...
  58. ncbi Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience
    D G Maluf
    Virginia Commonwealth University, Department of Surgery, Richmond, VA 23298, USA
    Transplant Proc 39:153-9. 2007
    ..Pretransplant HCC understaging contributes to posttransplant HCC recurrence after LTx...
  59. ncbi Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?
    M L Shiffman
    Hepatology Section, Medical College of Virginia Commonwealth University, Box 980341, Richmond, VA 23298, USA
    Curr Gastroenterol Rep 3:30-7. 2001
    ..The role PEG-interferons will play in patients who have either relapsed or failed to respond to previous interferon or interferon/ribavirin therapy remains to be defined...
  60. ncbi Primary sclerosing cholangitis: evaluation with MR cholangiography-a case-control study
    A S Fulcher
    Department of Radiology, Medical College of Virginia of Virginia Commonwealth University, Main Hospital, Richmond, VA 23298, USA
    Radiology 215:71-80. 2000
    ..To determine the accuracy of magnetic resonance (MR) cholangiography for detection of primary sclerosing cholangitis (PSC) and localization of PSC in the biliary tract...
  61. ncbi A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
    M L Shiffman
    Hepatology Section, Medical College of Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 117:1164-72. 1999
    ..Histological improvement is observed in some nonresponders. We conducted a randomized, controlled trial to determine if maintenance interferon therapy could prevent histological progression in this subset of nonresponders...
  62. ncbi Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy
    M L Shiffman
    Hepatology Section, Medical College of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Infect Dis 182:1595-601. 2000
    ..Persons with chronic HCV infection and persistently normal serum ALT levels have milder liver disease than, and respond to IFN therapy similarly to, persons with elevated ALT levels...
  63. ncbi Liver and intestine transplantation in the United States, 1995-2004
    M L Shiffman
    Hepatology Section and Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, VA, USA
    Am J Transplant 6:1170-87. 2006
    ..Although the intestine waiting list has more than doubled over the last decade, an increasing number of centers now perform intestinal transplantation with greater success...
  64. ncbi Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease
    R K Sterling
    Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Haemophilia 13:164-71. 2007
    ..These data support the hypothesis that HIV accelerates fibrosis progression in those coinfected with HCV and highlights the importance of liver histology in this population...
  65. ncbi Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
    A J Sanyal
    Division of Gastroenterology Hepatology, Department of Internal Medicine, Virginia Commonwealth University Medical College of Virginia, Richmond, Virginia 23298 0711, USA
    Gastroenterology 120:1183-92. 2001
    ....
  66. ncbi A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response
    M L Shiffman
    Hepatology Section, Medical College of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Infect Dis 184:405-9. 2001
    ..56%) and in patients with a virus titer < 2 x 10(6) copies/mL (93% vs. 43%). The results indicate that continuing ribavirin monotherapy after achieving a virologic response does not improve sustained virologic response...
  67. ncbi Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis
    M J Contos
    Department of Pathology, Division of Gastroenterology/Hepatology/Nutrition, Virginia Commonwealth University-Medical College of Virginia, Richmond, VA, USA
    Liver Transpl 7:363-73. 2001
    ..Despite the frequent histological recurrence of disease, clinical outcomes are similar to those of other groups of patients undergoing OLT...
  68. ncbi Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation
    V R Mas
    Department of Pathology, Virginia Commonwealth University, 403 North 13th Street, Richmond, VA 23298 0248, USA
    Clin Genet 65:191-201. 2004
    ..001) compared to patients without AR. There was an association between pro-inflammatory genotypes and HCV recurrence. Our data suggest that cytokine gene polymorphisms might play a role in AR and HCV recurrence in LTxRs...
  69. ncbi A balancing view: We cannot do it alone
    Mitchell L Shiffman
    Chief, Hepatology Section, Medical Director, Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Am J Gastroenterol 102:1841-3. 2007
  70. ncbi Benign recurrent intrahepatic cholestasis
    Velimir A Luketic
    Hepatology Section, Virginia Commonwealth University Health System, West Hospital, 14th Floor, 1200 East Broad Street, Richmond, VA 23219, USA
    Clin Liver Dis 8:133-49, vii. 2004
    ..Therapy is supportive and aimed at relieving pruritus and other complications of severe cholestasis until the episode resolves spontaneously...
  71. ncbi Chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298, USA
    Semin Liver Dis 24:1-2. 2004
  72. ncbi Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C
    M L Shiffman
    McGuire Research Institute, McGuire Veterans Administration Medical Center, Richmond, VA, USA
    Aliment Pharmacol Ther 31:969-78. 2010
    ..Increased apoptosis and activated caspases are present in these patients. PF-03491390 inhibits multiple caspases and lowers serum AST and ALT levels in patients with chronic liver diseases...
  73. ncbi Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Clin Gastroenterol Hepatol 2:183-97. 2004
  74. ncbi R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 48:385-97. 2008
    ..Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway...
  75. ncbi Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial
    Paul J Pockros
    Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, California 92037, USA
    Am J Gastroenterol 99:1298-305. 2004
    ..A significantly higher proportion of patients treated with the 180 microg dose of peginterferon alpha-2a had clinically significant histological improvement...
  76. ncbi High relapse rate seen at week 72 for patients treated with R1626 combination therapy
    Paul Pockros
    Hepatology 48:1349-50. 2008
  77. ncbi Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C
    Dickens Theodore
    University of North Carolina at Chapel Hill, North Carolina 27599, USA
    Dig Dis Sci 48:140-5. 2003
    ..Nelson-Aalen cumulative hazard estimates for the different race and dose combinations revealed that Caucasians who received daily interferon were most likely to have an initial response (logrank, P < 0.001)...
  78. ncbi Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
    Hepatology 48:1412-9. 2008
    ..However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result...
  79. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ....
  80. ncbi Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
    ..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
  81. ncbi Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 47:605-12. 2008
    ..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C...
  82. ncbi HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
    Hepatology 44:360-7. 2006
    ..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
  83. ncbi Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C
    Hongjin Huang
    Celera Diagnostics, Alameda, California, USA
    Gastroenterology 130:1679-87. 2006
    ..The aim of this study was to identify genetic polymorphisms that can predict the risk of advanced fibrosis in patients with CHC...
  84. ncbi Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
    Paul J Pockros
    Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 40:1450-8. 2004
    ..Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy...
  85. ncbi Adult living donor versus deceased donor liver transplantation: a 6-year single center experience
    Daniel G Maluf
    Division of Transplantation, Department of Surgery, Virginia Commonwealth University Health System, Richmon, VA, USA
    Am J Transplant 5:149-56. 2005
    ..Biliary complications were more common in A2ALLTx but were not associated with increased graft loss compared to ADDLTx...
  86. ncbi Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
    Stefan Zeuzem
    Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
    J Hepatol 39:106-11. 2003
    ..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders...
  87. ncbi A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
    Seng Gee Lim
    National University Hospital, Singapore
    Arch Intern Med 166:49-56. 2006
    ..CONCLUSION: In patients with chronic HBV, both positive and negative for HBe antigen, 48 weeks of emtricitabine treatment resulted in significant histologic, virologic, and biochemical improvement...
  88. ncbi A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Antivir Ther 10:635-43. 2005
    ..Larger, longer duration trials incorporating pegylated IFN would be required to determine whether this combination, alone or with RBV, would increase either early or sustained virological response rates...
  89. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  90. ncbi Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough
    Mitchell L Shiffman
    Gastroenterology 131:1339-41. 2006
  91. ncbi Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Hepatology 44:1675-84. 2006
    ..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
  92. ncbi Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  93. ncbi Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
    John G McHutchison
    Duke University and Duke Clinical Research Institute, Durham, NC 27705, USA
    N Engl J Med 357:2227-36. 2007
    ..We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis...
  94. ncbi Treating chronic hepatitis C virus after liver transplantation: balancing the risks against the chance for success
    Mitchell L Shiffman
    Liver Transpl 13:1088-91. 2007
  95. ncbi Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life
    Sanjeev Arora
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
    J Gastroenterol Hepatol 21:406-12. 2006
    ..HRQoL in the present population was also compared with HRQoL in patients with elevated ALT levels, observed in a previous study...
  96. ncbi Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
    William M Lee
    Control Clin Trials 25:472-92. 2004
    ..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity...
  97. ncbi Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy
    John G McHutchison
    Duke Clinical Research Institute, Division of Gastroenterology Duke University, Durham, North Carolina 27705, USA
    Am J Gastroenterol 102:880-9. 2007
    ..In the meantime, physicians must make the best possible use of the available options for managing anemia, especially in select patient groups who are most at risk for anemia and its complications...
  98. ncbi Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
    ....
  99. ncbi Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C
    Daniele Prati
    Ospedale A Manzoni, Lecco and IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy
    J Hepatol 44:679-85. 2006
    ..To clarify the role and interactions of viral and host factors in inducing liver cell injury, we examined the associations of several virological and metabolic variables with serum alanine aminotransferase levels...
  100. ncbi Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment
    K Rajender Reddy
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 5:124-9. 2007
    ..We evaluated the effects of ribavirin and peginterferon alfa-2a dose reductions on SVR in patients infected with HCV genotype 1...
  101. ncbi Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastroenterology 126:1302-11. 2004
    ..This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients...